β-Adrenergic blockade in cardiovascular disease

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 4, 2013, Pages 310-319

  Frishman, William H ^a  

^a WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

adrenergic pathways; angina; cardiomyopathy; heart disease; hypertension; molecular biology

Indexed keywords

ACEBUTOLOL; ALPHA ADRENERGIC RECEPTOR; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DICHLORISOPRENALINE; ESMOLOL; G PROTEIN COUPLED RECEPTOR; HORMONE; ISOPRENALINE; LABETALOL; METOPROLOL; NEBIVOLOL; NEUROTRANSMITTER; PINDOLOL; PRONETALOL; PROPRANOLOL; SOTALOL; TIMOLOL;

ACUTE HEART INFARCTION; ANGINA PECTORIS; BETA ADRENERGIC RECEPTOR BLOCKING; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; DRUG ACTIVITY; DRUG FORMULATION; DRUG STRUCTURE; HEART ARRHYTHMIA; HISTORY OF MEDICINE; HUMAN; HYPERTENSION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LUNG EDEMA; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; VASODILATATION;

Β-ADRENERGIC PATHWAYS; ANGINA; CARDIOMYOPATHY; HEART DISEASE; HYPERTENSION; MOLECULAR BIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; CARDIOVASCULAR DISEASES; HUMANS;

EID: 84879217294     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413484986     Document Type: Review

References (90)

1. Frishman WH Cardiovascular Pharmacotherapeutics. 3 rd ed. Minneapolis, MN: Cardiotext; 2011:57-85. Frishman WH Sica DA, ed. Minneapolis, MN: Cardiotext ; 2011: 57-85.
2. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol. 1948 ; 153 (3). 586-599
3. Frishman WH.. β-Adrenergic blockers: a 50 year historical perspective. Am J Therap. 2008 ; 15 (6). 565-576
4. Lefkowitz RJ. Seven transmembrane receptors: something old, something new. Acta Physiol. 2007 ; 190 (1). 9-19
5. Lefkowitz RJ. The superfamily of heptahelical receptors. Nat Cell Biol. 2000 ; 2: E133 - E136
6. Lefkowitz RJ. A magnificent time with the "magnificent seven" transmembrane spanning receptors. Circ Res. 2003 ; 92 (4). 342-344
7. Frielle T, Daniel KW, Caron MG, Lefkowitz RJ. Structural basis of β-adrenergic receptor subtype specificity studied with chimeric b1/b2-adrenergic receptors. Proc Natl Acad Sci U S A. 1988 ; 85 (24). 9494-9498
8. Dixon RA, Kobilka BK, Strader DJ, et al. Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin. Nature. 1986 ; 321 (6065). 75-79
9. Rasmussen SGF, Choi H-J, Rosenbaum DM, et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature. 2007 ; 450 (7168). 383-388
10. Service RF. Receptor scientists to receive chemistry Nobel. Science. 2012 ; 338 (6105). 313-314
11. Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic beta receptor antagonist. Lancet. 1964 ; 1 (7342). 1080-1081
12. Frishman WH. ß-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981 ; 305 (9). 505-506
13. Frishman WH. Clinical pharmacology of the Beta-Adrenoceptor blocking drugs. 1984 ;:
14. Koch-Weser J. Drug therapy: metoprolol. N Engl J Med. 1979 ; 301 (13). 698-703
15. Frishman WH. Cardiovascular Pharmacotherapeutics Manual. 2 nd ed. New York, NY: McGraw Hill; 2005:19-57. Frishman WH Sonnenblick EH Sica DA, ed. New York, NY: McGraw Hill ; 2005: 19-57.
16. Frishman WH.. Drug therapy. Pindolol: a new β adrenoceptor antagonist with partial agonist activity. N Engl J Med. 1983 ; 308 (16). 940-944
17. Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. Am Heart J. 1987 ; 113 (5). 1190-1198
18. Frishman W, Halprin S.. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part VII: new horizons in beta-adrenoceptor blocking therapy: labetalol. Am Heart J. 1979 ; 98 (5). 660-665
19. Frishman WH, Sica DA. Hypertension Primer: The Essentials of High Blood Pressure. 4 th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins; 2008:446-450. Izzo JL Sica D Black HR, ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins ; 2008: 446-450.
20. Frishman WH. Carvedilol. N Engl J Med. 1998 ; 339 (24). 1759-1765
21. Sule SS, Nebivolol Frishman W.. New therapy update. Cardiol Rev. 2006 ; 14 (5). 259-264
22. Frishman WH, Lazar EJ, Gorodokin G. Pharmacokinetic optimization of therapy with beta-adrenergic blocking agents. Clin Pharmacokinet. 1991 ; 20 (4). 311-318
23. Frishman WH.. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1: Pharmacokinetic and pharmacodynamic properties. Am Heart J. 1979 ; 97 (5). 663-670
24. Toprol XL Wilmington, DE: Astra Zeneca ; 2006 :
25. Coreg CR Research Triangle Park, NC: GlaxoSmithKlein ; 2007:
26. Frishman WH. Atenolol and timolol, two new systemic adrenoceptor antagonists. N Engl J Med. 1982 ; 306 (24). 1456-1462
27. Frishman WH. Nadolol: a new β-adrenoceptor antagonist. N Engl J Med. 1981 ; 305 (12). 678-684
28. Frishman WH, Furberg CD. Friedewald WT. β-Adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med. 1984 ; 310 (13). 830-837
29. Murthy VS, Frishman WH. Controlled beta receptor blockade with esmolol and flestolol. Pharmacotherapy. 1988 ; 8 (3). 168-182
30. Garnock-Jones KP.. Esmolol. A review of its use in the short-term treatment of tachy-arrhythmias and the short-term control of tachycardia and hypertension. Drugs. 2012 ; 72 (1). 109-132
31. Ward SA, Walle T, Walle UK, et al. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther. 1989 ; 45 (1). 72-79
32. Whitehouse Station, NJ: Merck & Co ; 2003:
33. Hamer J, Grandjean T, Melendez L, et al. Effect of propranolol (Inderal) in angina pectoris: preliminary report. Br Med J. 1964 ; 2 (5411). 720-723
34. Frishman WH.. Multifactorial actions of beta-adrenergic blocking drugs in ischemic heart disease. Circulation. 1983 ; 67 (suppl 1). Ill - Il8
35. Schroeder JS, Frishman WH, Parker JD, Angiolillo DJ, Woods C Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. Antman EM Sabatine MS, ed. Philadelphia, PA: Elsevier ; 2013: 83-130.
36. Madison, NJ: Wyeth Pharmaceuticals ; 2006:
37. Corona, CA: Watson Pharmaceuticals ; 2006:
38. Bristol, TN: Monarch Pharmaceuticals ; 2006:
39. Frishman WH Cardiac Arrhythmias: Mechanisms, Diagnosis and Management. Podrid PJ Kowey PR, ed. Baltimore, MD: Williams & Wilkins ; 1995: 421-433.
40. Halonen J, Loponen P, Jarvinen O, et al. Metoprolol versus amiodarone in the prevention of atrial fibrillation after cardiac surgery. A randomized trial. Ann Intern Med. 2010 ; 153 (11). 703-709
41. Parvez B, Chopra N, Rowan S, et al. A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol. 2012 ; 59 (1). 49-56
42. Bedford, OH: Ben Venue Labs ; 2004:
43. Montville, NJ: Berlex Labs ; 2004:
44. Cavusoglu E, Frishman WH. Sotalol: a new β-adrenergic blocker for ventricular arrhythmias. Prog Cardiovasc Dis. 1995 ; 37 (6). 423-440
45. Prichard BNC, Gillam PMS. Use of propranolol (Inderal) in the treatment of hypertension. Br Med J. 1964 ; 2 (5411). 725-727
46. Chobanian AV, Bakris GL, Black HR, et al. The National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA. 2003 ; 289 (19). 2560-2572
47. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice?. Lancet. 2004 ; 364 (9446). 1684-1689
48. Cutler JA, Davis BR. Should β blockers and diuretics remain as first-line therapy for hypertension?. Circulation. 2008 ; 117 (20). 2691-2705
49. Frishman WH. Saunders E. β-Adrenergic blockers. J Clin Hypertens (Greenwich). 2011 ; 13 (9). 649-653
50. Sarafidis P, Bogojevic Z, Basta E, et al. Comparative efficacy of two different β blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2008 ; 10 (2). 112-118
51. Ram CVS. β blockers in hypertension: truths and half-truths (editorial). J Clin Hypertens (Greenwich). 2008 ; 10 (7). 516-519
52. Weber MA, Bakris GL, Giles TD. Messerli FH. β blockers in the treatment of hypertension: new data, new directions. J Clin Hypertens (Greenwich). 2008 ; 10 (3). 234-238
53. Chrysant SG, Chrysant GS, Dimas B. Current and future status of beta blockers in the treatment of hypertension. Clin Cardiol. 2008 ; 31 (6). 249-252
54. Bakris GL, Fonseca V, Katholi RE, et al. GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004 ; 292 (18). 2227-2236
55. Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension. 2012 ; 59 (4). 893-898
56. Ram CVS. Beta-blockers in hypertension. Am J Cardiol. 2010 ; 106 (12). 1819-1825
57. Braunwald E. Treatment of the patient after myocardial infarction. N Engl J Med. 1980 ; 302 (5). 290-293
58. Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial. Eur Heart J. 1985 ; 6 (3). 199-226
59. The Lopressor Intervention Trial: multicenter study of metoprolol in survivors of acute myocardial infarction. Eur Heart J. 1987 ; 8 (10). 1056-1064
60. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet. 2001 ; 357 (9266). 1385-1390
61. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 1985 ; 72 (3). 536-546
62. LeJemtel TH, Sonnenblick EH, Frishman WH Hurst's The Heart. 11 th ed. New York, NY: McGraw Hill; 2004:723-762. Fuster V Alexander RW O'Rourke RA Roberts R King SB Prystowsky E Nash IS, ed. New York, NY: McGraw Hill ; 2004: 723-762.
63. Badve SV, Roberts MA, Hawley CM, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease. J Am Coll Cardiol. 2011 ; 58 (11). 1152-1161
64. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005 ; 26 (3). 215-225
65. A trial of the beta blocker bucindolol in patients with advanced chronic heart ailure. N Engl J Med. 2001 ; 344 (22). 1659-1667
66. Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967 ; 35 (5). 847-851
67. Winkle RA, Lopes MG, Goodman DS, Fitzgerald JW, Schroeder JS, Harrison DC. Propranolol for patients with mitral valve prolapse. Am Heart J. 1970 ; 93 (4). 422-427
68. Dorostkar PC, Eldar M, Belhassen B, Scheinman MM. Long-term follow up of patients with long QT syndrome treated with β blockers and continuous pacing. Circulation. 1999 ; 100 (24). 2431-2436
69. Kornbluth A, Frishman WH, Ackerman B. Beta-adrenergic blockade in children. Cardiol Clin. 1987 ; 5 (4). 629-649
70. Slater EE, DeSanctis RW. Dissection of the aorta. Med Clin North Am. 1979 ; 63 (1). 141-154
71. Rios AS, Silber EN, Bavishi N, et al. Effect of long-term β blockade on aortic root compliance in patients with Marfan syndrome. Am Heart J. 1999 ; 137 (6). 1057-1061
72. Beridze N, Frishman WH. Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis and prevention, and treatment of its complications. Cardiol Rev. 2012 ; 20 (1). 4-7
73. Frishman WH, Razin A, Swencionis C, et al. Beta-adrenoceptor blockade in anxiety states: a new approach to therapy. Cardiovasc Rev Rep. 1992 ; 8-13: 13
74. Kvetnansky R, Sabban EL, Palkovits M. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol Rev. 2009 ; 89 (2). 535-606
75. Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Less is more. Circulation. 2009 ; 120 (9). 725-734
76. Harte B, Jaffer AK. Perioperative beta-blockers in noncardiac surgery: evolution of the evidence. Cleveland Clinic J Med. 2008 ; 75 (7). 513-519
77. Mangano DT, Layug EL, Wallace A, Tateo I.. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter study of perioprative ischemia research group. N Engl J Med. 1996 ; 335 (23). 1713-1720
78. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999 ; 341 (24). 1789-1794
79. Shojania KG, Duncan BW, McDonald KM, Wachter RM, Markowitz AJ.. Making health care safer: A critical analysis of patient safety practices. Evid Rep Technol Assess (Summ). 2003 ; 43 (i-x). 1-668
80. Safe Practices for Better Healthcare - 2006 Update. Washington, DC: National quality Forum ; 2006:
81. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE Trial): a randomized controlled trial. Lancet. 2008 ; 371 (9627). 1839-1847
82. Fleisher LA, Poldermans D. Perioperative β blockade: where do we go from here? (comment). Lancet. 2008 ; 371 (9627). 1813-1814
83. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. Executive Summary: A report of the ACC/AHA Task Force on Practice Guidelines. Circulation. 2007 ; 116 (17). 1971-1996
84. Flu W-J, van Kujik J-P, Chonchol M, et al. Timing of pre-operative beta-blocker treatment in vascular surgery patients. J Am Coll Cardiol. 2010 ; 56 (23). 1922-1929
85. van Lier F, Schouten O, Hoeks SE, et al. Impact of prophylactic β-blocker therapy to prevent stroke after noncardiac surgery. Am J Cardiol. 2010 ; 105 (1). 43-47
86. Frishman WH, Clark A, Johnson B. Cardiovascular Pharmacotherapeutics. Frishman WH Sonnenblick EH, ed. New York, NY: McGraw Hill ; 1997: 1515-1559.
87. Elliott WJ, Meyer PM.. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007 ; 369 (9557). 201-207
88. Oka Y, Frishman W, Becker RM, et al. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 10. Beta-adrenoceptor blockade and coronary artery surgery. Am Heart J. 1980 ; 99 (2). 255-269
89. Frishman WH.. Beta-adrenergic blocker withdrawal. Am J Cardiol. 1987 ; 59 (13). 26F - 32F
90. Fonarow GC, Abraham WT. Albert NM, et al;OPTIMIZE-HF Investigators and Coordinators. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure. J Am Coll Cardiol. 2008 ; 52 (3). 190-199